Napo Pharmaceuticals, Inc.
Napo Pharmaceuticals Initiates Preclinical Development of a Novel CFTR Inhibitor Using Preclinical Resources Offered by the National Institute of Allergy and Infectious Diseases NIAID
Published in Genetics and Environmental Law Weekly, May 23rd, 2009
Napo Pharmaceuticals, Inc. which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases for the global marketplace in collaboration with local partners, is pleased to announce that pre-clinical drug development work is beginning at Menlo Park, California based Stanford Research International, (SRI), on its novel and proprietary second generation CFTR (cystic fibrosis transmembrane conductance regulator) inhibitors for the treatment of secretory diarrhea. These activities are being done using pre-clinical resources offered by the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
More Articles from Genetics and Environmental Law Weekly
- Coughlin Stoia Geller Rudman & Robbins LLP
Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Sequenom, Inc. - Johnson Bottini, LLP
Johnson Bottini, LLP Announces Review of Potential Violation of the Federal Securities Laws at Sequenom, Inc. - Johnson Bottini, LLP
Johnson Bottini, LLP Files Class Action on Behalf of Purchasers of Sequenom, Inc. - Adenomatous Polyp
Studies from N. Telang and colleagues yield new information about adenomatous polyp - Affymetrix, Inc.
Affymetrix Chosen as One of the Top Places to Work in the Bay Area - Allergies Immunology
Studies in the area of allergies immunology reported from Marmara University - More from this issue of Genetics and Environmental Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
